Shares of Bionano Genomics (NASDAQ: BNGO) soared 9.52% in a 24-hour period following the release of its third-quarter 2025 financial results, which significantly exceeded analyst expectations and showcased substantial improvements across key metrics.

The genome analysis company reported Q3 revenue of $7.4 million, representing a 21% increase from $6.1 million in the same period last year and beating the analyst consensus estimate of $6.871 million. This growth was primarily driven by increased utilization among routine users and expanding adoption of its Optical Genome Mapping (OGM) technology in key markets, including Japan.

Bionano's financial health showed marked improvement, with gross margin reaching 46%, a remarkable turnaround from the negative 139% reported in Q3 2024. The company also demonstrated strong cost management, reducing operating expenses by 66% to $11.9 million. These improvements reflect the success of Bionano's strategic shift towards driving consumables and software utilization among existing customers.

Looking ahead, Bionano provided an optimistic outlook for the fourth quarter and full year 2025. The company initiated Q4 2025 revenue guidance in the range of $7.5 to $7.9 million and reiterated its full-year 2025 revenue forecast of $26 to $30 million. Additionally, Bionano now expects to surpass 25 new OGM system installations for the full year 2025, exceeding previous expectations.

Erik Holmlin, CEO of Bionano Genomics, commented on the results, stating, "We believe our performance in the third quarter and year-to-date validates this strategic shift and demonstrates our turn toward sustainable growth as our business stabilizes." The strong quarterly performance and positive outlook have likely fueled investor optimism, contributing to the significant stock price increase.